EF-5

Research use only, not for human use.

EF-5 is a agent of hypoxia labeling. It is used to identify hypoxia in cells.

EF-5 is a agent of hypoxia labeling. It is used to identify hypoxia in cells.(In Vitro):EF-5 binding and metabolic reduction of the prodrugs are highly correlated in a panel of 14 hypoxic tumor cell lines. Overexpression of CYPOR causes similar 2- to 4-fold increases in EF-5 binding and metabolic reduction of tirapazamine and CEN-209 in SiHa and HCT116 cell lines. Which is similar enhancement of γH2AX formation.(In Vivo):EF-5 binding is a promising stratification biomarker for benzotriazine-N-oxide bioreductive prodrugs. Binding and detection using a monoclonal antibody in 9L gliomas is specific and oxygen dependent, following intravenous injection of EF-5. Modification of tumor hypoxia causes similar changes to the bioreductive activation of both agents, resulting in a strong correlation between EF-5 binding and CEN209-induced DNA damage at the individual tumor level. Detection of binding using fluorescence microscopy can be performed on frozen tissues; tissue sections can be counterstained with haematoxylin and eosin for light microscopic analysis. The distribution of hypoxia in a tumor can be inferred by examining individual tumor cells using flow cytometric techniques.

Overexpression of CYPOR induces similar 2- to 4-fold increases in EF-5 binding and metabolic reduction of tirapazamine and CEN-209 in SiHa and HCT116 cell lines, and similar enhancement of γH2AX formation. EF-5 binding and metabolic reduction of the prodrugs are highly correlated in a panel of 14 hypoxic tumor cell lines.

EF-5 binding is a promising stratification biomarker for benzotriazine-N-oxide bioreductive prodrugs. In HCT116 xenografts, CYPOR overexpression also significantly increases EF-5 binding and CEN-209 reduction, and modification of tumor hypoxia causes similar changes to the bioreductive activation of both agents, resulting in a strong correlation between EF-5 binding and CEN209-induced DNA damage at the individual tumor level. Following intravenous injection of EF-5, binding and detection using a monoclonal antibody in 9L gliomas is specific and oxygen dependent. Detection of binding using fluorescence microscopy can be performed on frozen tissues; tissue sections can be counterstained with haematoxylin and eosin for light microscopic analysis. Alternatively, the distribution of hypoxia in a tumor can be inferred by examining individual tumor cells using flow cytometric techniques.

EF5 | 2-Nitroimidazole

Others

Other Targets

Human Endogenous Metabolite

——

——

152721-37-4

302.161

C8H7F5N4O3

>98% (HPLC)

In Vitro:?DMSO : 125 mg/mL (413.69 mM)

[O-][N+](=O)c1nccn1CC(=O)NCC(F)(F)C(F)(F)F

——

(-20℃)

With Ice Pack

≥ 2 years